Shareholders to Vote on 14.7% Potential Dilution from Expanded Equity Plan and Officer Exculpation

summarizeSummary

Precision BioSciences is seeking shareholder approval for a significant expansion of its equity incentive plan, potentially diluting existing shareholders by 14.7%, and an amendment to exculpate officers from certain liabilities.

check_boxKey Events

• Annual Meeting Scheduled

  The Annual Meeting of Stockholders will be held virtually on Thursday, May 21, 2026, at 10:00 a.m. Eastern Time.

• Significant Equity Plan Expansion Proposed

  Shareholders will vote on amending the 2019 Incentive Award Plan to add 3,800,000 shares for issuance. This represents a potential dilution of approximately 14.73% based on current outstanding shares, aimed at retaining and incentivizing talent for clinical development.

• Officer Exculpation Amendment

  A proposal to amend the Certificate of Incorporation to provide officer exculpation, as permitted by Delaware law, will be voted on. This proposal previously failed to pass in 2025 due to not meeting the required vote threshold.

• High Vote Threshold for Key Proposals

  The officer exculpation amendment requires the affirmative vote of a majority of all outstanding shares, meaning abstentions and broker non-votes will count as votes against the proposal.

auto_awesomeAnalysis

This definitive proxy statement finalizes the terms of proposals for the upcoming annual meeting, following the preliminary proxy statement filed on March 27, 2026. The most significant proposal is the amendment and restatement of the 2019 Incentive Award Plan, which seeks to add 3,800,000 shares for issuance. Based on 25,803,199 shares outstanding as of March 25, 2026, this represents a potential dilution of approximately 14.73% if all shares are issued. The company states this expansion is critical for retaining and motivating talent, especially given that current outstanding options are significantly underwater and 2026 annual equity awards have not been granted due to limited shares. Additionally, shareholders will vote on an amendment to the Certificate of Incorporation to provide officer exculpation, a proposal that failed to pass last year despite strong support, which could impact executive accountability.